CareDx Details Transplant+ Roadmap, AlloHeme Timeline, and 2026 Outlook at Raymond James Conference

CareDx (NASDAQ:CDNA) executives outlined the company’s transplant-focused strategy, recent financial performance, and 2026 priorities during remarks at the Raymond James Institutional Investor ...

CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx’s Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets

The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...
Business Wire

CareDx Celebrates 1 Million Organ Transplants and 100,000 Patient Milestone

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value ...
Business Wire

CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...

CareDx outlines $420M-$444M 2026 revenue target amid solution selling and cell therapy pipeline expansion

CareDx expects full year 2026 revenue of $420 million to $444 million. Testing Services revenue is projected at $306 million to $326 million, with total testing volume of 220,000 to 228,000 tests. The ...
The Motley Fool

Why Shares of CareDx Are Jumping Friday

CareDx specializes in testing services and products to help transplant patients, and is a leading provider of genomics-based information for transplant patients. Sales of its tests are keenly affected ...
Business Insider

CareDx Agrees to Acquire TransChart and Expands EMR Connectivity to Over 90 Centers

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of ...
AOL

CareDx President and CEO Sells 19,000 Shares for $412,000

19,480 shares directly sold for a total of ~$412,200 (weighted average price $21.16) across two transactions on Jan. 21 and Jan. 22, 2026. The sale represented 3.16% of direct holdings, reducing ...
Contract Pharma

CareDx Names COO to Additional CFO Post

CareDx is appointing its Chief Operating Officer (COO), Keith Kennedy, to the additional role of Chief Financial Officer (CFO ...
Morningstar

CareDx to Report First Quarter 2025 Financial Results

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients ...
Morningstar

CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value ...